UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人の腎移植における免疫抑制誘導療法 induction immunosuppressive therapy in renal transplantation in adults
2. 急性腎同種移植片拒絶反応：治療 acute renal allograft rejection treatment
3. 心臓移植における免疫抑制療法の導入および維持 induction and maintenance of immunosuppressive therapy in cardiac transplantation
4. 肺移植後の免疫抑制の導入 induction immunosuppression following lung transplantation
5. 再生不良性貧血：予後および治療 aplastic anemia prognosis and treatment

English Journal

Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies.

Kang HJ1, Hong KT1, Lee JW1, Kim H1, Park KD1, Shin HY1, Lee SH2, Yoo KH2, Sung KW2, Koo HH2, Lee JW3, Chung NG3, Cho B3, Kim HK3, Koh KN4, Im HJ4, Seo JJ4, Jung HJ5, Park JE5, Lee YH6, Lim YT7, Lim YJ8, Kim SY8, Yoo ES9, Ryu KH9, Lee JH10, Park JA11, Park SK12, Ahn HS13; Korean Society of Pediatric Hematology-Oncology.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.Biol Blood Marrow Transplant.2016 Aug;22(8):1455-9. doi: 10.1016/j.bbmt.2016.04.003. Epub 2016 May 8.
Hematopoietic stem cell transplantation (HSCT) is a curative therapy for severe aplastic anemia (SAA); however, the optimal conditioning regimen for HSCT with an unrelated donor has not yet been defined. A previous study using a fludarabine (FLU), cyclophosphamide (Cy), and antithymocyte globulin (A
PMID 27090956

Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Ravinet A1, Cabrespine A, Socié G, Milpied N, Yakoub Agha I, Nguyen S, Michallet M, Menard AL, Maillard N, Mohty M, Suarez F, Huynh A, Marchand T, Deteix C, Cassuto JP, Maury S, Chevallier P, Reman O, Peffault de Latour R, Bay JO.
Transplantation.Transplantation.2016 Aug;100(8):1732-9. doi: 10.1097/TP.0000000000000976.
BACKGROUND: The impact of antithymocyte globulin (ATG) in the setting of a myeloablative conditioning transplantation remains controversial, especially when using bone marrow (BM) as the stem cell source.METHODS: We therefore conducted a retrospective analysis to investigate the impact of ATG in pat
PMID 26528768

Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients Receiving Thymoglobulin induction -A single center experience.

Puttarajappa C1, Bhattarai M1, Mour G1, Shen C2, Sood P1, Mehta R1, Shah N1, Tevar AD3, Humar A3, Wu C1, Hariharan S1.
Clinical transplantation.Clin Transplant.2016 Jul 16. doi: 10.1111/ctr.12810. [Epub ahead of print]
BACKGROUND: The burden of cytomegalovirus infection in CMV high-risk (donor positive to recipient negative) kidney transplant recipients getting thymoglobulin induction and six months of valganciclovir is not well characterized. Additionally, the role of post-prophylaxis surveillance remains unclear
PMID 27423138